Genome & Company, a new microbiome-based drug development company, announced on the 8th that it has appointed Yoo-seok Hong as its general representative.
Genome & Company plans to go through the process of appointing Hong Yoo-seok as the new CEO through the regular meeting of shareholders and board of directors next year.
Yoo-seok Hong, the new CEO of Genome & Company, graduated from Hankuk University of Foreign Studies and received a master’s degree in business administration from the Wharton School at the University of Pennsylvania, USA. Since then, Hong has served as CEO of Lilly Korea, senior executive in charge of strategy and business development at the Emerging Market Business Headquarters at Eli Lilly Headquarters, CEO of Handok Teva, and CEO of GSK Korea.
He was the first Korean to be appointed as the representative of the North American corporation of a multinational pharmaceutical company, and since 2018 he has served as the pharmaceutical business representative of GSK Canada. He recently worked as CEO of D&D Pharmatech.
The company expects that the new general manager, Hong, will put the commercialization of candidate materials under clinical trials on the right track based on the experience he has accumulated in the global pharmaceutical industry for more than 30 years. years.
Meanwhile, CEO Seo Young-jin, who has led Genome & Company since 2022, will step down on the 31st of this month.
After joining the company in June 2018, CEO Seo led the KONEX listing and KOSDAQ transfer listing, and was responsible for establishing business strategies and systematizing the operation of the internal organization.
Bae Ji-soo, CEO of Genome & Company, said, “This recruitment is a decision to strengthen business development (BD) and expand our global business. Based on Hong’s experience in various international pharmaceutical companies, many are expected achievements.”
